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The UK Biobank imaging enhancement of 100,000
participants: rationale, data collection, management
and future directions
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Simon Sheard 4, Stephen M. Smith 5, Cathie L. M. Sudlow2,
Paul M. Matthews 13,14 & Naomi E. Allen 1,14
UK Biobank is a population-based cohort of half a million participants aged 40–69 years
recruited between 2006 and 2010. In 2014, UK Biobank started the world’s largest multi-
modal imaging study, with the aim of re-inviting 100,000 participants to undergo brain,
cardiac and abdominal magnetic resonance imaging, dual-energy X-ray absorptiometry and
carotid ultrasound. The combination of large-scale multi-modal imaging with extensive
phenotypic and genetic data offers an unprecedented resource for scientists to conduct
health-related research. This article provides an in-depth overview of the imaging enhance-
ment, including the data collected, how it is managed and processed, and future directions.
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Imaging provides structural and functional information oninternal anatomy and physiological processes. Its use in clin-ical practice has transformed the diagnosis, management and
treatment of disease. Imaging can detect asymptomatic pathology
before disease development and thus can be used to screen high-
risk populations to support precision and preventative medicine.
In some cases, imaging can provide insights into the biological
mechanisms underlying exposure-disease associations.
Large-scale population-based prospective studies can facilitate
the identification of imaging measures as targets for prevention or
provide an insight into disease mechanisms. Although some
epidemiological studies have incorporated imaging measures,
these have usually been limited to a specific imaging modality or
body region (such as the brain or heart), have often been
restricted to selective population subgroups at high risk for cer-
tain diseases and have included no more than a few thousand
participants. For example, the first cohort studies to use magnetic
resonance imaging (MRI), such as the Rotterdam study and the
Multi-Ethnic Study of Atherosclerosis (MESA), included <5000
participants1,2.
However, to assess the moderate associations that may exist
between genetic and lifestyle factors and imaging-derived phe-
notypes (IDPs), or between IDPs and subsequent risk of a wide
range of diseases, it is necessary to perform imaging in very large
numbers of healthy individuals as only a relatively small pro-
portion of them will develop any particular condition during
follow-up. Furthermore, in the era of ‘Big Data’, large, diversely
phenotyped cohorts are essential to maximise recent develop-
ments in artificial intelligence (AI). To address this challenge,
more ambitious multi-modal imaging protocols have been initi-
ated in longitudinal cohorts, including brain and body MRI in the
German National Cohort on 30,000 participants3, and MRI of the
brain, blood vessels, heart and liver in the Canadian Partnership
for Tomorrow Project (CPTP) for 10,000 participants (see www.
partnershipfortomorrow.ca).
Here, we provide an overview of the programme currently
underway in UK Biobank (UKB), the largest and most detailed
imaging study to date. The UKB imaging enhancement aims to
perform brain, cardiac and abdominal MRI, full body dual-energy
X-ray absorptiometry (DXA) and a carotid ultrasound scan on
100,000 of the existing 500,000 UKB participants before the end
of 20234. As of early 2020, over 45,000 participants have under-
gone an assessment, already making the UKB imaging enhance-
ment by far the largest multi-modal imaging study in the world.
This article outlines the scientific rationale and processes involved
in collecting, curating and disseminating the imaging data for
research purposes, and describes recent developments, such as the
initiative to repeat the imaging of at least 10,000 participants.
The launch of UK Biobank
Between 2006 and 2010, 9.2 million women and men aged 40–69
who were registered with the UK’s National Health Service (NHS)
were sent postal invitations to attend one of 22 UKB assessment
centres in England, Scotland and Wales5. Of these, ~500,000
(5.5%) individuals joined the study. Although UKB is not
representative of the UK population, the large sample size and
heterogeneity of measures nonetheless enable a valid assessment
of many exposure–outcome relationships to be made. During the
baseline assessment, extensive sociodemographic, lifestyle and
health-related information was collected through a touchscreen
questionnaire and verbal interview, and a wide range of physical
measures were performed4,6. Participants also provided biological
samples that have been used to perform genotyping7 and hae-
matological and biochemistry assays for the full cohort8. Once
recruitment was fully underway, additional measures were
incorporated into the baseline assessment, including tests of
hearing and arterial stiffness (n= ~200,000), a cardiorespiratory
fitness test (n= ~100,000) and various eye measures (n=
100,000–150,000). Since the baseline visit, subsets of participants
have supported additional data collection through various
enhancements to the study. These have included: a full repeat of
the baseline assessment (n= ~20,000, 2012–2013), collection of
physical activity data over 7-days by wearing accelerometers (n=
~100,000, 2013–2015 and n= ~2500 on four occasions,
2018–2019) and regular online questionnaires covering a variety
of topics such as diet, cognitive function, occupational history,
mental wellbeing, gastrointestinal health and pain (sent to
~330,000 participants with email addresses; ~35–50% response
rate for each questionnaire).
All participants provided consent for their health to be
followed-up through linkage to health-related records, which
currently includes death, cancer and hospital inpatient records for
the full cohort. Primary care data are also available for ~45% of
the cohort (with data for the remaining participants pending).
Together, these electronic medical record data capture informa-
tion on type and date of diagnosis and symptoms, procedures and
operations, prescriptions, test results and referrals by general
practitioners.
UKB received approval from the National Information Gov-
ernance Board for Health and Social Care and the National
Health Service North West Centre for Research Ethics Committee
(Ref: 11/NW/0382). UKB is compliant with both the previous
Data Protection Act and the more recent General Data Protection
Regulation (GDPR) implemented in 2018. For the GDPR, parti-
cipants were contacted by email or post to explain how UKB
meets the requirements of the new regulations (https://www.
ukbiobank.ac.uk/gdpr/).
Rationale for multi-modal imaging on 100,000 participants in
UK Biobank. When the original UKB protocol was reviewed in
2006, the UK Biobank International Peer Review Panel recom-
mended exploring the feasibility of conducting enhancements in
large subsets of the cohort. The inclusion of imaging measures
was deemed of value and further consultation with the wider
scientific community was recommended. Consequently, UKB
established an expert Imaging Working Group in 2011 who, after
consultation with over 100 imaging specialists worldwide,
developed an imaging protocol that aimed to maximise the sci-
entific value of the imaging data collected while also being
achievable at scale (i.e., non-invasive with short acquisition
times).
A key requirement was the inclusion of several imaging
modalities that could provide precise and reliable information on
multiple organ systems as opposed to single body sites. The
protocol thus includes collection of imaging data on the brain,
heart, large blood vessels, body composition, bone and joints.
This provides researchers with the opportunity to use measures
from different organ systems to explore the multifactorial biolo-
gical mechanisms of complex diseases. For example, the diversity
of data could contribute to a better understanding of the
relationships between systemic health and dementia through
capture of data regarding the structure and function of the brain
(brain MRI) in conjunction with adiposity (body MRI and DXA)
and vascular risk factors (cardiac MRI and carotid ultrasound)9.
The integration of multiple ‘gold-standard’ imaging measures can
also be used to calibrate and expand upon the data collected at the
baseline assessment. For example, the whole-body DXA scan
complements measures of bone density obtained from the heel
ultrasound performed at baseline. Further, body MRI and DXA
could provide more detailed data on body composition and fat
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distribution than that provided by the bioimpedance measures.
This will support more refined analyses of body composition,
such as whether disease risk varies in those with a normal body
mass index (BMI) but who have a high visceral fat content10.
Another consideration for the Imaging Working Group was
how many participants to image. This was done by ultimately
balancing estimates of the power of potential future nested case-
control studies with pragmatic considerations based on costs and
feasibility. Approximately 5000 and 10,000 cases are required to
detect an odds ratio of 1.5 and 1.33 with 80% power, respectively,
when the exposure prevalence is 10%11. Although imaging
100,000 participants is unprecedented, it is clear this is the sample
size needed to capture sufficient cases to reliably explore a wide
range of associations.
Protocols of the UK Biobank imaging enhancement. Following
ethical approval, a pilot study of ~5,000 participants was per-
formed between 2014 and 2015 to demonstrate the feasibility of
high-throughput imaging and to finalise the imaging protocols
required for the main phase. Funding was then released to extend
the imaging enhancement to an additional 95,000 participants,
with data collection estimated to finish by 2023. The imaging
assessment takes place in dedicated, purpose-built centres based
in Stockport (termed Central), Newcastle-upon-Tyne (North),
Reading (South-East) and Bristol (South-West). The locations
were selected to minimise travel times for the majority of parti-
cipants, based on driving times and availability of public trans-
port links, as travelling time was recognised as one of the main
determinants as to whether a participant was likely to attend
or not.
Invitation process. Invitations for the Central region of the UK
began in April 2014, followed by the Northern region in April
2017, the South-East region in June 2018 and the South-West
centre in February 2020. Initially, invitations were sent by email
as this is the most cost-effective means of communicating with
participants. However, as not all participants provided an email
address, postal invitations began in early 2020 to provide all
participants the opportunity to attend, should they wish to do so.
Therefore, all surviving UKB participants will be invited, except
for those who have informed UKB they no longer wish to be
contacted or now live outside the UK (<0.5% of participants to
date). Participants are provided with comprehensive information
about the project, including an invitation letter briefly describing
what the assessment visit involves and an information leaflet
describing the individual scans, eligibility criteria and benefits and
risks of participation as well as links to a dedicated UKB imaging
website (https://imaging.ukbiobank.ac.uk/). If interested, partici-
pants are asked to telephone the Participant Resource Centre who
makes an initial assessment as to whether the potential partici-
pants are eligible for inclusion in the enhancement (e.g., the MRI
scans are not safe for individuals who have metal implants or who
have had certain surgeries) and for tolerability (e.g., claus-
trophobia). Completion of the full protocol is not possible for
those unable to lie still, hold their breath voluntarily or hear
instructions. Participants who have MR-compatible metal
implants in their body (not limbs) are also excluded as these can
affect the quality of the scan in regions close to the metal and
reduce their value for research purposes.
Reminder emails are sent to non-responders 2 weeks, 4 weeks,
6 months, 12 months and 24 months after the initial invitation.
All email invitations and reminders contain a decline link, where
participants can opt out of receiving subsequent invitations. To
obtain imaging data on 100,000 participants, an attendance rate
of at least 20% of the 500,000 UKB participants is required. To
date, this has been achieved, with 31% of invited participants
expressing an interest, of which 71% are eligible and have booked
an appointment; of these, 97% have attended an imaging
assessment centre (Fig. 1). Approximately 12% of participants
book an appointment in response to an initial invitation, with
response rates of 7% after the 2 week reminder and a further 4%
after the 4-week reminder.
General imaging process. The target throughput for each ima-
ging centre is 18 participants per 12-hour working day, and the
centres are open every day (except for the Christmas and Easter
holidays). When fully operational, a monthly average of 17 par-
ticipants per day is achieved (with 95% attendance rate). Each
centre is staffed by six radiographers, three healthcare assistants, a
laboratory specialist, a healthcare assistant team leader and a
centre manager, with a lead radiographer and MR physicist
providing support across all centres. Four sub-specialist third
party consultant radiologists, each with experience in brain,
cardiac, abdominal or musculoskeletal imaging, review scans that
are flagged by radiographers as having a potentially serious
incidental finding.
UK Biobank participants
503,000
Invited to imaging enhancement
44%
Expressed interest in attending 
imaging enhancement 
31%
No response = 53%
Do not wish to attend = 17%
Confirmed participants
71%
Ineligible after pre-screen
29%
Participants attended
97% 
Have not yet attended
3%
Complete core data for:
Brain MRI = 89%
Cardiac MRI = 92%
Abdominal MRI = 91%
DXA = 97%
Carotid Doppler ultrasound = 97%
Fig. 1 Flow chart of participation in the UK Biobank multi-modal imaging
study. Note that as the invitation process is ongoing, this flow chart is only
accurate as of early 2020. For example, some participants classified as ‘no
response’ might attend the imaging enhancement in future.
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On arrival at the assessment centre, the participant’s eligibility is
again checked with a radiographer, and electronic consent is
obtained to confirm that the participant understands the nature of
the study and potential implications, such as the detection and
feedback of incidental findings. There are four imaging stations:
one consisting of the brain MRI, another one covering both the
cardiac and abdominal MRI, one for DXA and a final station for
carotid ultrasound. To fully maximise the use of the facilities, three
participants go to a separate station simultaneously and serially
rotate through different stations. Once participants have finished
the imaging assessments, they repeat all the measures collected at
the baseline assessment, except for the eye examinations, 4-lead
electrocardiogram (ECG) during exercise and saliva sampling.
General imaging quality control. A centralised training and
monitoring team is responsible for quality assurance across all
imaging centres. All staff members undergo a six-week training
programme before centres open, with monthly training provided
by the MR physicist. To ensure fully harmonised imaging data are
acquired across centres, identical scanner models, software,
adjustment and tuning methods, types of coils and protocols are
used. Quality assurance and control measures are also in place
including a standardised training programme for all radio-
graphers in each centre, system acceptance testing, standard
operating procedures, as well as routine phantom measurements,
regular servicing and performance checks that are conducted by a
dedicated UKB physicist. The radiographer visually inspects the
MRI images for quality control purposes while participants are
undergoing scanning and immediately after acquisition. Quality
control assessments consisting of qualitative and quantitative
comparisons conducted by external imaging experts for each
modality confirmed that images acquired during the pilot study
were of excellent quality for research purposes (Table 1).
Table 1 Quality control performed on brain, cardiac and abdominal MRI, DXA and carotid ultrasound sequences/images during
the pilot study.
Imaging modality Assessor Sequence/images assessed Number images
assessed
Quality control metrics Passed quality
control (%)
Brain MRI FMRIB T1 2957 Similarity to template after non-linear
registration (alignment)
99
Signal to noise 99
Contrast to noise 99
T2/Flair 2957 Similarity to T1 after linear registration 99
T2* (magnitude image) 2957 Similarity to T1 after linear registration 100
Resting fMRI 2957 Similarity to T1 after linear registration 100
Temporal signal to noise 99
High subject head motion 96
Task fMRI 2957 Similarity to T1 after linear registration 100
Temporal signal to noise 98
High subject head motion 96
Diffusion MRI 2957 Similarity to T1 after linear registration 100
BioMedIA T1 100 Whole brain tissue segmentation 100
INRIA Asclepios T1 100 Cortical segmentation 100
Cardiac MRI BioMedIA Short-axis, cine views 100 Segmentation of myocardium and
ventricular blood pools
100
INRIA Asclepios Short-axis cine views 100 Visual inspection 85
Automated displacement and strain
analyses
100
QMUL All images 100 Manual “reference” analysis of all
proposed IDPs feasible, excellent intra-
observer variability of all IDPs
100
Oxford ShMOLLI TI map 100 TI mapping 90
Yale Short-axis, cine views 100 Visual inspection, processing
pipeline works
100
Leeds CISTIB/LICAMM Short-axis, cine views 100 Visual assessment, segmentation of
myocardium and blood pools, image
registration
100
Auckland Automatic in line LV
function
100 Comparison to manual analysis 99
Oxford UKB cluster Automatic in line LV
function
3456 Automated extraction of LV measures 99
Abdominal MRI BioMedIA Dixon whole body 100 “Stitching” 6 scan stations for whole body
reconstruction (24 scans per subject)
93
Prof. Jimmy Bell T1 100 Visual 96
T2* 100 Visual 95
Dixon 100 Visual 96
AMRA Dixon abdomen
station images
100 Semi-automated tissue segmentation 99.7
Dixon thigh station images 100 Semi-automated multi-atlas tissue
segmentation
98.1
Perspectum Liver 100 Semi-automated fibrosis index 96
100 Semi-automated steatosis measure 99
100 Semi-automated haemosiderosis measure 99
DXA Dr Nicola Crabtree DXA 1837 Visual comparison versus gold standard 99
Quantitative comparison of all measures
versus those re-derived by expert
99
GE iDXA device DXA 3222 Total and region-specific bone mineral
density measures
99–100
Total and region-specific body composition
measures
96–100
Carotid ultrasound UKB senior radiographer
and Prof. Paul Leeson
Right and left carotid images 1994 Visual comparison versus expert gold
standard
99
Panasonic imaging device Right and left carotid images 3107 Right and left carotid intima-media
thickness
96–99a
DXA dual-energy X-ray absorptiometry, fMRI functional magnetic resonance imaging, IDP imaging-derived phenotype, LV left ventricle, MRI magnetic resonance imaging, UKB UK Biobank.
a96% ≥2 sets of measures obtained from both left and right carotids; 99% ≥1 set of measures obtained from left or right carotid.
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Incidental findings. UKB developed an approach to managing
the clinical review of images acquired in consultation with sta-
keholders, funders and the UKB Ethics and Governance Council
(now the Ethics Advisory Committee). Consistent with the
practices established for other data collected by UKB, participants
are informed that the data collected is intended for research use
only, that the scans will not be routinely assessed for evidence of
disease and that individual results will not be made available to
them (detailed information on incidental findings can be found at
https://imaging.ukbiobank.ac.uk). However, and consistent with
the approach adopted for incidental findings during the original
assessment visit, if while scanning a participant, a radiographer
observes an incidental finding that might be clinically serious or
life-threatening then the relevant scans undergo further review by
a specialist radiologist, who determines independently whether
UKB should notify the participant and their general practitioner.
All participants explicitly consent to participate in the imaging
enhancement on this basis.
This approach was evaluated through comparison with
systematic radiology review of all images from the first 1000
imaged participants. Compared to the systematic radiologist
review, radiographer flagging resulted in substantially fewer
participants with potentially serious incidental findings (179/1000
[17.9%] versus 18/1000 [1.8%]) but a higher proportion with
serious final diagnoses (21/179 [11.7%] versus 5/18 [27.8%]).
Radiographer flagging missed 16/21 serious final diagnoses (false
negatives) while systematic radiologist review generated large
numbers of non-serious final diagnoses (158/179, false positives).
All participants who were notified of a potentially serious
incidental finding consulted their GP, and 90% had some further
clinical assessment (most commonly additional imaging (79%), or
referral to a specialist (64%)). Some participants reported that
feedback of their incidental findings had a negative impact on
their emotional wellbeing, insurance status or finances, or work
and leisure activities (17%, 9% and 6%, respectively).
In light of these findings from the pilot and with additional
advice from UKB’s independent Ethics and Governance Council,
we concluded that the proposed UKB imaging incidental findings
protocol to use radiographer flagging (and not systematic
radiologist review) provides an acceptable balance of benefit
versus harm to the participants, as detailed elsewhere12.
Rationale, protocol and data processing for each imaging
modality Brain MRI. There are several neuroimaging methods
that can measure different aspects of the brain. However, MRI is
unique as it can capture high-resolution structural and functional
information in a single examination in a non-invasive manner (i.e.,
with no use of non-ionising radiation). Both structural and func-
tional brain measures show promise as markers to guide strategies
for disease prevention, monitoring of disease progression or as
predictive markers for disease risk (e.g., by identifying neuroana-
tomical markers related to the risk of developing dementia)13.
However, although brain MRI has been used commonly for smaller
clinical and non-clinical neuroscientific research14, its use in large-
scale population-based epidemiological studies like UKB is limited.
The brain MRI protocol is performed using a 3 Tesla Siemens
Skyra scanner (Siemens Healthineers, Erlangen, Germany) with
VD13 software and a 32-channel head coil. The full examination
lasts approximately 35 min. Table 2 reports the selected
parameters of the brain MRI protocols. The protocol includes
three structural MRI scans; T1, T2 fluid attenuation inversion
recovery (FLAIR) and susceptibility-weighted MRI (swMRI), as
well as diffusion MRI (dMRI) and resting and task functional
MRI (fMRI). T1 scans allow precise volumetric measures of the
whole brain, as well as specific cortical and subcortical regions.
The T2 FLAIR scan identifies changes that might be indicative of
inflammation or tissue damage. For instance. an increased signal
in the white matter is associated with an increased risk of
dementia and stroke15. swMRI is sensitive to increased iron
content as a result of microbleeds or chronic microglial activation
in the context of neurodegeneration16. dMRI reflects structural
connectivity and tissue microstructural features describing white
matter integrity. Resting fMRI is performed on an individual who
is not engaged in any particular activity or task and can provide
indices related to the functional connectivity between brain
regions independent of external stimuli. By contrast, task fMRI is
performed on an individual to whom stimuli are repetitively
delivered that engage sensory-motor and cognitive processes of
interest. The UKB task fMRI protocol is based on the Hariri faces/
shapes ‘emotion’ task, selected because it engages a wide range of
cognitive and sensory-motor systems and a wide range of
normative data is available17.
An automated processing pipeline for brain image analysis and
quality control was established for UKB at the University of
Oxford’s Wellcome Centre for Integrative Neuroimaging (WIN/
FMRIB). This pipeline is primarily based around FSL (FMRIB’s
Software Library), and other packages such as FreeSurfer18,19.
When acquired at the imaging centres, the images are reconstructed
from k-space on the scanner computer and saved initially as
DICOM files. The processing pipeline then converts these files to
the NIFTI format and undertakes pre-processing (e.g., correcting
for head motion and other artefacts) as well as automated quality
control that identifies issue with the equipment (e.g., coil failure)
and artefacts specific to the participant or scanning session (e.g.,
excessive head movement). The NIFTI files for the T1 and T2 scans
are the default version provided to researchers, as these are suitably
“defaced” to remove the possibility of re-identification of any
individual participant. In 99.5% of cases, the defaced mask does not
overlap with the brain mask19. The pipeline also automatically
generates thousands of IDPs, such as regional grey matter volume
from T1 scans, volume of white matter hyperintensities from
Table 2 Brain MRI protocol parameters.
Modality Duration (mins) Resolution (mm3) Matrix Other parameters
T1 MPRAGE 4:54 1.0x1.0x1.0 256x256x208 TI/TR= 880/2000 ms, R= 2
Resting fMRI 6:10 2.4x2.4x2.4 88x88x64 TE/TR= 39/735 ms, α= 51°, MB= 8
T2 FLAIR 5:52 1.0x1.0x1.05 256x256x192 TI/TR= 1800/5000 ms, R= 2
Diffusion MRI1 7:08 2.0x2.0x2.0 104x104x72 TR= 3600 ms, 50 directions/shell, b= 0, 1000,
2000 s/mm2, α= 51°, MB= 3
Susceptibility-weighted 2:34 0.8x0.8x3.0 288x256x48 TE1/TE2/TR= 9.4/20/27 ms, R= 2
Task fMRI 4:13 2.4x2.4x2.4 88x88x64 TE/TR= 39/735 ms, α= 51°, MB= 8
FLAIR, fluid-attenuated inversion recovery; MB, multi-band factors; MPRAGE, magnetization-prepared rapid acquisition with gradient echo sequence for T1-weighted contrast; R, parallel imaging
acceleration factor
1Multi-band excitation and reconstruction protocols were kindly provided by the Center for Magnetic Resonance Research in the Department of Radiology of the University of Minnesota, USA.
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T2 scans, fractional anisotropy measures from dMRI scans and
signal changes in response to stimuli from task fMRI scans. These
IDPs have been made available to researchers in batched uploads to
the resource since the imaging enhancement began. In-depth
information on the brain MRI protocol and quality control process
have been published elsewhere18,19.
Cardiac MRI. Cardiac MRI captures information related to both
the structure and function of the heart and can provide a range of
measures which have been implicated in cardiovascular disease
such as left ventricular mass, left ventricular ejection fraction, left
atrial volume and aortic stiffness20–23. Prior to UKB, the largest
studies of cardiac MRI were the Multi-Ethnic Study of Athero-
sclerosis (5000 participants)2, the Dallas Heart Study (3000 par-
ticipants)24 and the Jackson Heart Study (2000 participants)25.
Although these studies are valuable resources for population
health research, their main focus is on cardiovascular disease and
risk factors. The sheer size of UKB offers unique opportunities to
investigate the subclinical cardiovascular mechanisms related to a
wide range of cardiovascular and non-cardiovascular diseases,
including research to identify early markers of pathology and
their genetic and lifestyle determinants.
The cardiac MRI scan is performed using a Siemens 1.5 Tesla
MAGNETOM Aera scanner (Siemens Healthineers, Erlangen,
Germany) with VD13A software and a spine and body flex matrix
coil. No pharmacological stressor or contrast agent is used. The
protocol lasts ~20 min and provides structural and functional
measures of the left and right ventricles, left and right atria and
the aorta, including volumes, changes in volumes during cardiac
cycle, cardiac wall thickness and mass, tissue motion using
tagging and thoracic aorta size and distensibility. Table 3 reports
the selected parameters of the cardiac MRI protocols.
At present, only a limited range of features are automatically
extracted from the cardiac scanner, such as inline ventricular
function (which assesses left ventricular contours and volume). A
group based at Queen Mary University, London, and the University
of Oxford has created a cardiac structural MRI segmentation
reference by manual analysis of the first 5000 scans26,27. However,
the scale of the imaging enhancement has accelerated efforts to
develop automated processing tools that can extract a wider range of
cardiac phenotypes in order to maximise the scientific utility of these
data. A range of algorithms to automatically segment and assess the
quality of the remaining cine cardiac MR images are now being
made openly available28–30. An automated large-scale image quality
control, analytics and image-based phenotype extraction has been
established in collaboration with the University of Leeds Centre for
Computational Imaging & Simulation Technologies in Biomedicine
(CISTIB) based on a private deployment of the MULTI-X secure-
based platform (www.multi-x.org)30,31. In-depth information on the
cardiac MRI protocol have been published elsewhere26,32.
Abdominal MRI. Anthropometric measures, such as weight,
height, BMI and waist-to-hip ratio, are commonly collected in
epidemiological studies and have informed our knowledge about
the role of adiposity with disease risk. However, these measures
are fairly crude indicators of body composition and provide little
information on the type and distribution of body fat, which have
been shown to be important predictors of disease risk33. For
example, visceral obesity (abdominal fat surrounding the internal
organs) has been linked to an increased risks of type II diabetes,
cardiovascular disease, cancer and mortality34–36. Accumulation
of ectopic fat in the liver can cause hepatic steatosis (fatty liver),
which is associated with insulin resistance and hepatocellular
carcinoma37,38. MRI is considered the gold standard for body
composition measurement and offers an unprecedented oppor-
tunity to measure internal and ectopic fat content, as well as
whole-body and site-specific fat and muscle volume. However,
abdominal MRI has not been conducted in any large-scale studies
previously. Consequently, UKB is an unprecedented resource to
further our understanding of how body fat composition and
distribution influences disease risk.
The abdominal MRI protocol follows the cardiac examination on
the 1.5 T scanner, employing relevant elements of spine and body
matrix coils. The scan includes sequences that last 10min. Table 4
reports the selected parameters of the abdominal MRI protocols.
Localisation is performed relative to the jugular notch, which is
the centre position of the first stage of the Dixon imaging. The
examination includes the LiverMultiScan protocol, developed by
Perspectum Diagnostics (Oxford, UK), which images the liver by
a single transverse slice at the porta hepatisis using two different
sequences39. A single breath-hold cardiac-gated Modified Look-
Locker Inversion Recovery sequence (shMOLLI) for T1 mapping
is acquired. A single breath-held spoiled-gradient-multi-echo
sequence in the same slice position is performed. Together, these
allow multiple measures sensitive to liver fibrosis, iron content
and fat39. For volumetric evaluations of the pancreas, a 3D VIBE
is acquired in transverse orientation centred at the position of the
pancreas. A shMOLLI sequence is performed using the same
parameters as for the liver. Finally, multi-echo sequence is used
(10 different echoes) to allow measurements of iron and fat
content.
For quality control, images are visually inspected immediately
after reconstruction at the scanner. Fully automated tools are not
currently available for extracting quantitative parameters from
the images. However, research groups are developing semi-
automated tools to extract fat, muscle and organ measures,
including visceral and ectopic fat content40 and liver measures41.
In-depth information on the abdominal MRI protocol have been
published elsewhere40,42,43.
Dual-energy X-ray absorptiometry. DXA captures precise site-
specific (e.g. proximal femur, lumbar spine) measures of bone
Table 3 Cardiac MRI protocol parameters.
Protocol name Resolution (mm3) Matrix Other parameters
LAX 1.9x1.9x6 210x208x50 TE/TR= 1.16/32 ms, α= 65°, R= 2
SAX 1.8x1.8x8 210x208x50 TE/TR= 1.1/32 ms, α= 10°, R= 2
shMOLLI 0.9375x0.9375x8 variablex384x7 TE/TR= 1.073/400 ms, α= 35°, R= 2
Aorta 1.58x1.58x6 240x196x100 TE/TR= 1.17/28 ms, α= 66°, R= 2
LVOT 1.9x1.9x6 210x208x50 TE/TR= 1.16/32 ms, α= 65°, R= 2
FLOW 1.77x1.77x6 192x92x30 TE/TR= 2.47/37.12 ms, α= 20°, R= 2
TAGGING 1.38x1.38x8 256x256xvariable TE/TR= 3.89/40.95 ms, α= 12°
LAX, long-axis view imaging; LVOT, left ventricular outflow tract/aortic valve imaging; R, parallel imaging acceleration factor; SAX, short-axis view imaging; shMOLLI, shortened modified Look-Locker
imaging
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mineral density and whole-body composition (e.g. bone, fat and
lean mass), with no extensive additional processing and analy-
sis44. DXA is regarded as the ‘gold-standard’ tool for the diag-
nosis of osteoporosis45, and can also provide information
concerning the joint and its articular surfaces that is relevant to
osteoarthritis46. Although several population-based cohorts have
performed DXA scanning on several thousand participants47–49,
UKB will be about 10-times bigger and uniquely offers the
opportunity to compare body composition measures across DXA
and MRI modalities. It also enables the investigation of how bone
and joint integrity measures are related to a broad range of health
outcomes and their genetic and environmental determinants.
An iDXA instrument (GE-Lunar, Madison, WI, USA) is used
in the imaging enhancement to measure several body sites using a
protocol that lasts 20 min. The instrument captures high-
resolution images of the whole-body, proximal femur, spine
(from L4 to T4) and knees, which can be used to identify joint
pathology, vertebral fractures and other phenotypes using
advanced techniques50. Measures of bone mineral density and
body composition are automatically derived from the scanner and
are transferred to UKB requiring little post-processing. Other
measures are also being derived, including indices of bone
strength, such as trabecular bone score (a measure of bone
texture) and hip structural analysis, as well as hip and knee
osteoarthritis phenotypes. High-resolution images of hips, knees,
whole body, anteroposterior lumbar spine and lateral thoraco-
lumbar spine are exported as DICOM files for further analysis by
researchers.
All radiographers are trained according to a protocol
harmonised across the scanning sites to allow consistent, accurate
participant positioning and image acquisition. The DXA instru-
ment undergoes manufacturer’s daily quality control and local
calibration using a phantom (GE-Lunar, Madison, WI). Periodic
calibration across sites and over time is undertaken using a
European spine phantom to ensure consistent measures are
obtained51. An automated quality control protocol, where specific
DXA analysis results (femoral neck bone mineral density, dual
femur total bone mineral content, trunk fat mass, age, DXA
weight) are checked for consistency, is being developed and a
random sample of 50 scans per site are checked each quarter, with
further radiographer training recommended as appropriate.
Carotid ultrasound. Carotid ultrasound imaging provides
information about the health of the carotid arteries including
measures of vessel thickness (expressed as carotid intima-media
thickness (CIMT)) and vessel wall and plaque volume52. These
measures are useful indicators of vascular pathology, such as
atherosclerotic burden, and are predictive of various
cardiovascular diseases, such as stroke, myocardial infarction and
coronary heart disease53.
Participants are imaged using a CardioHealth Station (Pana-
sonic Healthcare Corporation of America, Newark, NJ, USA),
which has a 9MHz linear array transducer. The protocol lasts 10
min. Both right and left carotid arteries are imaged using a 2D
sweep along the transverse plane from below the carotid
bifurcation to below the jaw and is repeated along the
longitudinal plane. The CIMT is measured at predefined angles:
150° and 120° on the right carotid artery, and 210° and 240° on
the left. A marker is placed on the screen to guide the operator in
aligning the flow divider and a 10 mm region of interest box is
overlaid and automatically tracks the far wall of the common
carotid. After three consecutive cardiac cycles, the image auto-
freezes in end-diastole and records the mean, maximum, and
minimum CIMT for each angle of acquisition.
All the CIMT measures are automatically generated by the
device and do not require further post-processing. However, the
quality of data acquisition depends highly on the operator and
hence quality control is a high priority. Trained radiographers
complete a manual assessment of image quality for all scans
against agreed criteria, based on expected key features of the
image and automated CIMT measurement54. Although vessel
wall volume and plaque volume are not available as automated
measures within the CardioHealth station, bespoke analysis tools
to extract these measures are in development. In-depth informa-
tion on the carotid ultrasound protocol and quality control
process have been published elsewhere54.
12-lead electrocardiogram. Participants also undertake a 12-lead
ECG assessment (GE Cardiac Acquisition Module CAM-14)
during the imaging assessment. ECG can be used to detect
abnormalities related to heart rhythm and electrical activity and
to make inferences regarding cardiac structure55. Both major and
minor ECG abnormalities have been associated with an increased
risk of coronary heart disease56 and cardiovascular-related mor-
tality57. In UKB, the ECG is performed with participants at rest
on the same couch used for the carotid ultrasound. The leads are
placed on the right and left forearms proximal to wrists, right and
left lower legs proximal to ankles and chest with the measurement
lasting 20 s. After acquisition, a summary page displays the results
for the operating staff member to either mark as ‘complete’ or
provide a reason for incomplete assessment. The ECG system
includes interpretation software (GE CardioSoft system) that
provides an automated output for the detection of arrhythmias
and metrics reflecting electrical activity, such as PR interval, QRS
duration and QT interval. The raw ECG datasets are also made
available for research use.
Table 4 Body MRI protocol parameters.
Protocol Name Resolution (mm3) Matrix Other parameters
Dixon Stage 1 2.232x2.232x3 224x168x64 TE/TR= 2.39, 4.77/6.67 ms, α= 10°
Dixon Stage 2 2.232x2.232x4.5 224x174x44 TE/TR= 2.39, 4.77/6.69 ms, α= 10°
Dixon Stage 3 2.232x2.232x4.5 224x174x44 TE/TR= 2.39, 4.77/6.69 ms, α= 10°
Dixon Stage 4 2.232x2.232x4.5 224x174x44 TE/TR= 2.39, 4.77/6.69 ms, α= 10°
Dixon Stage 5 2.232x2.232x3.5 224x162x72 TE/TR= 2.39, 4.77/6.69 ms, α= 10°
Dixon Stage 6 2.232x2.232x4 224x156x64 TE/TR= 2.39, 4.77/6.69 ms, α= 10°
shMOLLI Liver 1.146x1.146x8 384x288x7 TE/TR= 1.93/480.6 ms, α= 35°, R= 2
LMS 1.719x1.719x10 256x232x6 TE/TR= 1.2 (min) TE/TR= 7.2 (max)/14 ms, α= 5°
VIBE 1.1875x1.1875x1.6 320x260x52 TE/TR= 1.15/3.11 ms, α= 10°, R= 2
shMOLLI Pancreas 1.146x1.146x8 384x288x7 TE/TR= 1.93/480.6 ms, α= 35°, R= 2
ME GRE Pancreas 2.5x2.5x6 160x160x10 TE/TR= 2.38(min) TE/TR= 23.8(max)/27 ms, α= 20°
LMS, LiverMultiScan protocol incorporating abdominal T1-weighted T2* and proton density fat fraction mapping; ME GRE, multi-echo gradient echo imaging; R, parallel imaging acceleration factor;
shMOLLI, shortened modified Look-Locker imaging; VIBE, volumetric interpolated breath-hold examination
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15948-9 REVIEW ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2624 | https://doi.org/10.1038/s41467-020-15948-9 | www.nature.com/naturecommunications 7
Characteristics and data completeness for the first 40,000
participants. Table 5 summarises selected demographic and
lifestyle characteristics for the participants who completed ima-
ging between 2014 and early 2020. A high proportion have
undertaken other UKB data enhancements, with almost half
(44%) having worn the 7-day accelerometer, compared with 19%
of the whole UKB cohort, and most have completed the web-
based questionnaires.
More than 80% of participants who have undertaken imaging
have complete ‘core’ datasets for each of the imaging modalities,
and over 90% have complete ‘core’ datasets for the DXA and
carotid ultrasound (Fig. 1). For the small proportion of
participants with incomplete data, approximately half arise from
participant specific issues, such as inability to comply with the
demands of the protocol; for example, failure to complete the
brain MRI because of excessive movement (1%) or a sudden
episode of claustrophobia (2.2%). Other reasons for missing data
for the brain MRI include scanner failures (2 %), staffing issues
(0.4%) or scheduling problems (1.1%).
Data generation, storage and access. Around 2.7 GB of imaging
data are generated per participant, with 500TB of storage esti-
mated to be required for 100,000 participants. Imaging data are
transferred from the scanners to the data repository via a custom-
built Picture Archiving and Communication System (PACS), at
the Nuffield Department of Population Health, University of
Oxford. The imaging system was initially set up around a com-
mercial PACS system, but due to the quantity and nature of the
imaging workflow, a fully customised solution was essential.
Images on the PACS are automatically checked for completeness
and then replicated in a core archive. Incomplete datasets are
flagged for manual checking and fault resolution. The PACS also
has a workflow to manage and track potentially serious incidental
findings, enables secure access for radiologists and specialists to
view image data, write and review reports, and prepare the cor-
respondence and imaging data for the NHS. All personal iden-
tifiers are removed before providing participant data to
researchers.
The UKB resource is available to all bona fide researchers who
are associated with academic and commercial institutions any-
where in the world58. Researchers must first register with UKB
and can then apply to access the data for specified research
projects via an online Access Management System (www.
ukbiobank.ac.uk/register-apply), which consists of a brief appli-
cation form and the selection of data-fields. Applications can be
broad in scope as long as the aims of the project are well-defined
and consist of health-related research in the public interest.
UKB became available for researchers to access in 2012, with
imaging data for the first 5,000 participants available in mid-2015
and for ~40,000 participants by early 2020. Researchers can
request IDPs or the scans if they wish to extract novel features.
Example images for each modality are provided on the UKB Data
Showcase (http://biobank.ndph.ox.ac.uk/showcase/). Imaging data
are uploaded to the resource every 6–12 months in batches of
5,000–10,000 participants, so researchers can update their analyses.
Researchers are expected to publish and return their results (i.e.,
code/syntax, derived variables) so that any imaging-derived
phenotypes generated as part of a research project are incorporated
back into the UKB resource and are available to others.
Repeat multi-modal imaging on 10,000 participants. Although
imaging 100,000 participants is a unique and powerful
enhancement to the UKB resource, these data are currently only
collected at a single time point and many valuable insights could
be gained from observing change in imaging phenotypes over
time. Serial measures are necessary to explore trajectories and
progression of pathological processes and several measures col-
lected over time typically provides a more accurate insight than a
single, cross-sectional measure. For example, measures of change
in structural brain MRI are a much better predictor of conversion
from mild cognitive impairment to Alzheimer’s disease compared
to a single measure59. Using cardiac imaging, left ventricular mass
has been shown to decrease with age in men when examined
cross-sectionally, but to increase with age when examined long-
itudinally in the same study, demonstrating the importance of
multiple measures60. Repeated measures also enable researchers
to account for random measurement error and within-person
variability, known as regression dilution bias, that can bias
observed associations towards the null61.
Recognising this, at least 10,000 of the imaged participants will
be re-invited to undergo a complete repeat of the imaging
enhancement. Invitations to participants who had attended the
Table 5 Characteristics and data completion for the first 48,000 participants who attended the imaging enhancement.
Imaged participants Non imaged participants
At imaging % At baseline % At baseline %
Characteristic
Age, mean (SD) 64 (7.5) 55. (7.6) 56. (8.1)
Females 52 52 55
Professional qualifications 74 73 58
Non-white ethnic background 3 3 6
BMI≥ 30 kg/m2 19 18 25
Current smoker 3 6 11
Completed following enhancements
Physical activity monitor 44 18
Online questionnaires
24 h dietary recall at least once 60 32
Cognitive function 54 22
Occupational history 55 21
Mental health 69 27
Digestive health 77 30
Repeat of baseline assessment during 2011–2012 (not imaging) 17 3
BMI body mass index, SD standard deviation.
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first imaging assessment at least 2 years previously were initiated
in May 2019 for the Central region and July 2019 for the
Northern region. Although still in the early stages, the response
rate has been high (more than 65%), with ~3200 participants
having booked appointments to attend repeat imaging within the
first seven months.
Discussion and future directions. By early 2020, almost 50,000
participants had undertaken the imaging assessment, with
100,000 participants expected to have completed the protocol by
the end of 2023. Of these, 10,000 participants are expected to have
undergone a repeat of the imaging assessment by 2023. Imaging
at such a large scale is unprecedented1,2. However, as only a small
proportion of individuals will go on to develop certain diseases
and the influences of risk factors may be small, a large sample size
(i.e., in the order of 100,000) is necessary to adequately detect
reliable associations with all but the most common conditions
and strongest risk factors. The wealth of phenotypic and genetic
data available on the UKB cohort will enable researchers to study
how imaging phenotypes are related to a wide range of lifestyle,
environmental and genetic factors, and to study how these
antecedent factors influence disease risk through changes in tissue
structure and/or function.
An advantage of the imaging enhancement is that it is
embedded in an existing cohort study that has thousands of
researchers worldwide actively working with the data. As of early
2020, over 1750 UKB projects were underway, two-thirds of
which had received IDPs, and a quarter had received the scans.
Hence, while still in the early stages of data acquisition, the
imaging data that has been collected (and which is being made
available to researchers in regular tranches) has received wide-
spread interest worldwide and is already being used to address a
range of novel research questions.
Published output to date has primarily focused on exploring
cross-sectional associations between lifestyle factors with IDPs.
For example, higher BMI and waist-to-hip ratio have both been
associated with smaller volumes in different regions of the
brain62,63, while hypertension and other vascular risk factors have
been linked with abnormal white matter microstructure and other
adverse brain measures64,65. These early findings could help us
understand the mechanism through which vascular risk factors
are related to neurodegenerative diseases, such as Alzheimer’s
disease9. A range of cardiovascular risk factors have also been
associated with cardiac structure and function66–68, and other,
less obvious, associations have been identified, such as with air
pollution69, menopausal hormonal therapy70 and lung function71.
Novel findings are already emerging, for example diabetes has
been shown to be associated with abnormal morphologies and
function in all four heart chambers, whereas previously only the
left ventricle was typically thought to be affected by diabetes72.
In addition to lifestyle factors, there is great interest in exploring
how genetic variation is associated with imaging phenotypes to
better assess the genetic determinants of early disease and to help
understand the biological mechanisms underlying disease associa-
tions. For example, genome-wide association studies on over 3000
functional and structural brain imaging phenotypes on 12,000
participants identified novel associations between genes linked to
iron transport and IDPs related to lower cognitive function73.
Other studies have explored the genetic determinants of regional
brain volumes and measures of white matter integrity74–79. One
study provided evidence that genes associated with left-
handedness are linked to cortical regions involved in language80.
These studies are both novel and powerful as previous genetic
studies have tended to focus on a narrow selection of imaging-
related outcomes and incorporate data from multiple studies (with
heterogeneous data collection and analytic techniques), to achieve
a sufficiently large sample size.
The brain IDPs are extracted through a fully automated
pipeline (established by WIN/FMRIB) and are therefore relatively
easy to integrate into the resource and provide for research use.
At present, IDPs from the other imaging modalities are extracted
using semi-automated or manual pipelines, which are more time
consuming and less readily available. However, the sheer scale of
the imaging data available in UKB is facilitating the development
of new methods to extract novel IDPs structural measures from
the cardiac scans28,81,82, body compositional measures from the
abdominal MRI40,43,83, and measures of fat and iron from the
liver MRI39,42,84. In accordance with UKB access policies, all
results, including individual-level IDPs and the methods used to
generate them by research users of the resource, are returned to
be integrated into the resource so that they can be made available
to everyone approved to use the data.
The imaging enhancement has coincided with recent major
advances in applications of machine learning and AI, in particular
the development of computational algorithms that can learn how
to extract meaningful information from raw images85,86. This
includes the automated segmentation and classification of
anatomical structures as well as the detection of abnormalities.
Recently, machine learning techniques such as deep learning have
demonstrated enormous potential as diagnostic tools by identify-
ing conditions on a par with experts, for example skin cancer and
diabetic retinopathy29,87. Development of these algorithms
requires training on thousands of images to produce robust
results, making UKB an ideal dataset. Machine learning
techniques were applied to UKB cardiac MRI scans to identify
aortic valve malformations and subsequent major cardiac events88.
Although this analysis was performed on only the first 10,000
imaged participants, it clearly demonstrates the use of UKB as a
valuable resource for AI research using the imaging data.
A key aspect of UKB is its prospective study design, which will
enable research concerning the associations between IDPs and a
range of incident health outcomes. This is important, as cross-
sectional analyses cannot determine temporality of an observed
association and are particularly affected by reverse causation, i.e.,
when the outcome influences the exposure. Data from national
death and cancer registries and hospital inpatient data are
available for the full cohort, with data from primary care made
available for about half the cohort in late 2019. Primary care will
be immensely valuable for capturing conditions often diagnosed
outside of a hospital inpatient setting. For example, compared to
using only death registry and hospital admissions records,
incorporating primary care data could increase the number of
incident cases identified in the UKB cohort by 2021 by ~150% for
dementia (5400 to 13,000 cases), by ~50% for stroke (8300 to
12,900 cases), by over 100% for chronic obstructive pulmonary
disorder (13,300 to 30,600 cases) and by ~100% for Parkinson’s
disease (2000–4000 cases). Additional case ascertainment is being
aided by online questionnaires which are being developed to
collect information on outcomes poorly captured through
medical records, such as those related to cognitive function,
digestive health, pain, sleep and mental health.
External academic and commercial groups are also enhancing
the resource by performing cohort-wide assays on the biological
samples, including whole genome sequencing (funded by
government, charity and industry), exome sequencing (led by
Regeneron and a consortium of industry partners), leukocyte
telomere length (University of Leicester, UK) and NMR-
metabolomics (Nightingale Health). In line with UKB return of
results policy, these data will be returned to UKB and integrated
into the resource to be accessible to all researchers registered with
an approved application.
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Conclusion
UKB is currently on course to collect detailed, high quality multi-
modal imaging data on the brain, the heart, abdominal compo-
sition, bones, joints and blood vessels on 100,000 participants.
UKB has also begun the process of performing repeat imaging on
at least 10,000 participants. The amount of imaging data collected
on such a large number of participants is truly unique. Yet it is
the combination of these data with the wealth of other pheno-
typic, genetic and medical record information available in UKB
that provides a powerful resource to address previously unans-
werable research questions. Traditionally, imaging data might be
perceived to be of value mainly to specialists in a narrow range of
fields. However, researchers from many disciplines, including, but
not limited to, epidemiologists, neuroscientists, statisticians,
geneticists and psychologists, can and are using the IDPs already
available from the imaging scans to conduct health-related
research to provide new insights into the prevention, diagnosis
and treatment of disease.
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